TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10793299
Drug: Nutritional antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional antioxidant supplements, hydroxyl radical scavengers, and iron‐binding agents
Study: 2072407
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus tamoxifen (30 mg daily for 48 weeks)
Study: 6849755
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone (Solu‐Medrol)
Study: 6849755
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg naloxone (Nalonee)
Study: 31420399
Drug: SensiumVitals monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SensiumVitals monitoring system (wearable wireless patch)
Study: 27586837
Drug: Control (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1.8 g leucine, n = 7)
Study: 27586837
Drug: Leucine (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (3.5 g leucine, n = 8)
Study: 24182692
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone (T) @40 mg/ml, 1.5 ml, injections every three weeks until complete flattening or eight sessions
Study: 24182692
Drug: Intralesional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional verapamil (V) @2.5 mg/ml, 1.5 ml, injections every three weeks until complete flattening or eight sessions
Study: 17391154
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.4, 0.8, 1.4 U/kg)
Study: 17391154
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (0.4, 0.8, 1.4 U/kg)
Study: 17391154
Drug: NN344 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN344 and insulin detemir
Study: 24725803
Drug: All insulin
Normalized name: Small Insulin Syringe 1cc 31g
Approvals — FDA: no, EMA: no, PMDA: no
Description: All insulin preparations
Study: 12025879
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received no special treatment)
Study: 7621730
Drug: Aspiration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration of insulin syringe during injection
Study: 7621730
Drug: Non-aspiration technique
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspiration technique for insulin administration
Study: 2883055
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin (0.85 mU X kg‐1 X min‐1 during 2 min followed by 8 min with no insulin)
Study: 2883055
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin (0.17 mU X kg‐1 X min‐1)
Study: 2883055
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin
Study: 26876240
Drug: Combined orbital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined orbital radiotherapy and steroid pulse therapy (SRT group)
Study: 26876240
Drug: Steroid pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pulse therapy only (ST group)
Study: 9240727
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg clodronate tablet
Study: 9240727
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clodronate capsule
Study: 2880804
Drug: ICI 118551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551, 50 mg t.i.d. orally
Study: 10657404
Drug: Selfotel (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selfotel (1.5 mg/kg intravenous dose within 6 hours of stroke onset)
Study: 26897029
Drug: BBaRTS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BBaRTS intervention (children's storybooks with embedded BCTs, parenting skills, and oral health messages)
Study: 21060724
Drug: 5-Loxin(®) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Loxin(®) 100 mg daily for 90 days
Study: 21060724
Drug: Aflapin(®) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflapin(®) 100 mg daily for 90 days
Study: 15167206
Drug: Constant drinkers
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant drinkers consuming 0.1‐19.9 g alcohol per day
Study: 15167206
Drug: Constant drinkers
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant drinkers consuming 20.0‐39.9 g alcohol per day
Study: 15167206
Drug: Female constant
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female constant drinkers consuming 0.1‐19.9 g daily alcohol
Study: 9693202
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. + Amoxicillin 500 mg q.i.d. + Clarithromycin 400 mg b.i.d. (OAC)
Study: 9693202
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. + Clarithromycin 400 mg b.i.d. (OC)
Study: 8207292
Drug: SY5555 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 150 mg x 3/day for 7 days
Study: 8207292
Drug: SY5555 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 300 mg x 3/day for 7 days
Study: 8207292
Drug: SY5555 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 150 mg x 3/day
Study: 8207292
Drug: SY5555 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 300 mg x 3/day
Study: 8207292
Drug: SY5555 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SY5555 treatment
Study: 30292578
Drug: Hybrid closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid closed-loop therapy
Study: 30292578
Drug: Sensor-augmented pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented pump therapy (Control)
Study: 28939581
Drug: VZV vaccination
Normalized name: VZV immune globulin
DrugBank: Human varicella-zoster immune globulin (DB11621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VZV vaccination (live-attenuated VZVOka vaccine)
Study: 21685235
Drug: Lapatinib (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1500 mg/d) for three weeks
Study: 16487220
Drug: TDS-testosterone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDS-testosterone (50 mg)
Study: 16487220
Drug: Androgel (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgel (1% topical testosterone gel)
Study: 12066421
Drug: Fictitious medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fictitious medication with varying sample sizes (4, 6, 8, or 40 trials) and contingency (delta P = .20, .40, .60, or .80)
Study: 10321913
Drug: 17beta-estradiol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (all doses)
Study: 8621845
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (NS), 4 mg inhaled, 4 times daily for 3 months
Study: 8621845
Drug: Placebo, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 4 times daily for 3 months
Study: 1774443
Drug: Parlodel LAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parlodel LAR (long-acting intramuscularly injectable depot preparation of bromocriptine)
Study: 7048890
Drug: Fructose sweetened
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose sweetened cakes and ice creams
Study: 7048890
Drug: Ice creams
Normalized name: Camphor Ice Topical Product
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice creams
Study: 7048890
Drug: Sucrose sweetened
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose sweetened cakes and ice creams
Study: 30239596
Drug: Panfacial aesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panfacial aesthetic treatment
Study: 26088885
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (Lorazepam + 1st AED)
Study: 26088885
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (with addition of 2nd AED)
Study: 26088885
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (with addition of 3rd AED)
Study: 17689931
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS (ineffective treatment)
Study: 9146770
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily + 1000 mg amoxycillin b.d. (days 5-14)
Study: 9146770
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Study: 9146770
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Study: 9146770
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg omeprazole b.d. + 1000 mg amoxycillin b.d. (days 5-14)
Study: 7711430
Drug: Recombinant interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 and interferon-alpha 2b (rIL-2 and IFN-alpha 2b) administered subcutaneously for 6 weeks (3 treatment cycles, each with 3 weeks of administration)
Study: 3330985
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg, twice daily; n = 7)
Study: 19217154
Drug: Ustekinumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (90 mg or 63 mg) every week for 4 weeks (weeks 0-3)
Study: 19217154
Drug: Ustekinumab (63
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (63 mg) at weeks 12 and 16
Study: 19217154
Drug: Ustekinumab (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (90 mg or 63 mg)
Study: 16708768
Drug: Gynostemma pentaphyllum
Normalized name: GYNOSTEMMA PENTAPHYLLUM TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gynostemma pentaphyllum (GP) extraction 80 mL for 4 months after 2 months of controlled diet
Study: 16708768
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for 4 months after 2 months of controlled diet
Study: 15636412
Drug: Multicomponent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent treatment intervention (MTI)
Study: 11422765
Drug: Parenteral iron
Normalized name: Iron, parenteral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral iron administration (iron dextran 100 mg at ten consecutive dialysis sessions)
Study: 11422765
Drug: No parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No parenteral iron administration
Study: 8501147
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU GH (iv infusion)
Study: 8501147
Drug: 5 IU
Normalized name: Vitamin E 15 IU/0.3 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU GH (im bolus injection)
Study: 8501147
Drug: 48 IU
Normalized name: Acetylcarnitine/alpha Tocopherol/alpha Tocotrienol/Ascorbic Acid/beta Tocopherol/Betaine/Coenzyme Q10/Cyanocobalamin/delta Tocopherol/delta Tocotrienol/Docosahexaenoic Acid/Eicosapentaenoic Acid/Folic Acid/gamma Tocopherol/gamma Tocotrienol/Grape Seed Extract/Lecithin/Levocarnitine/Magnesium/Niacin/Olive Oil/Pyridoxine Hydrochloride/Selenomethionine/Taurine/Thioctic Acid 12.5 MG-30 IU-75 MCG-250 MG-3 IU-50 MG-30 MG-50 MCG-48 IU-125 MCG-60 MG-90 MG-0.5 MG-180 IU-1100 MCG-50 MG-50 MG-50 MG-100 MG-25 MG-215 MG-25 MG-50 MCG-25 MG-25 MG Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 IU GH (iv infusion)
Study: 8501147
Drug: 30 micrograms/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms/h GHRH (iv infusion)
Study: 3125077
Drug: Enterococcus lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enterococcus lactic acid bacteria strain SF68 (two capsules three times daily)
Study: 3125077
Drug: Lactulose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (30 ml four times daily)
Study: 26717867
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) pre-operatively for CAS
Study: 26717867
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) post-operatively for CAS
Study: 26717867
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) pre-operatively for CEA
Study: 26717867
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) post-operatively for CEA
Study: 26717867
Drug: Mono antiplatelet
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono antiplatelet therapy (MAPT) post-procedural
Study: 26717867
Drug: Testing for
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing for antiplatelet therapy resistance
Study: 20919760
Drug: Treatment Advocacy
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Advocacy Program (TAP)
Study: 16313478
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-oestradiol plus 1 mg DRSP
Study: 16313478
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-oestradiol plus 2 mg DRSP
Study: 16313478
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-oestradiol plus 3 mg DRSP
Study: 12484506
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor plus spironolactone (25 mg) for 60 weeks
Study: 12484506
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor alone for 60 weeks
Study: 7590617
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg given at 11:00 p.m. on on-call night
Study: 7590617
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg given at 11:00 p.m. on control night
Study: 2075246
Drug: Intra-amniotic PGF2
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic PGF2 alpha combined with hypertonic saline, intravenous oxytocin, and a hygroscopic cervical dilator (Dilapan)
Study: 29871023
Drug: Adjunctive homeopathy
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive homeopathy
Study: 27290985
Drug: RSGB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSGB group (lidocaine 1% 7 ml under ultrasound guidance)
Study: 19222821
Drug: Rapid Diagnostic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Diagnostic Test (RDT) before treatment decision
Study: 19222821
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management (presumptive treatment)
Study: 11593318
Drug: Bu/Mel/T (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu/Mel/T (for patients with prior dose-limiting radiation)
Study: 8106787
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg over 48 h)
Study: 8106787
Drug: Chloroquine plus
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine plus Clindamycin (5 mg/kg every 12 h for 6 doses)
Study: 8106787
Drug: Quinine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (12 mg/kg every 12 h for 6 doses)
Study: 8106787
Drug: Quinine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine plus Clindamycin (5 mg/kg every 12 h for 6 doses)
Study: 6228504
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A
Study: 1139857
Drug: Commercial carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial carbamazepine tablets
Study: 1139857
Drug: Propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylene glycol solution
Study: 31118491
Drug: Low-dose helical
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose helical CT (LDCT) screening
Study: 23601084
Drug: TM38837 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM38837 500 mg
Study: 23601084
Drug: TM38837 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TM38837 100 mg
Study: 23601084
Drug: Rimonabant 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 60 mg
Study: 9209174
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (9 g/d)
Study: 28922651
Drug: Bupropion +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion + nicotine lozenge
Study: 23674879
Drug: Medical adhesive
Normalized name: Medical Adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical adhesive spray (group A)
Study: 11343664
Drug: Unfractionated heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, enoxaparin, or reviparin for at least 4 days, plus a coumarin derivative with a target INR of 2.0 to 3.0 starting on the 1st or 2nd day of treatment.
Study: 1495357
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin/5-FU) followed by definitive radiation (6600 to 7600 cGy)
Study: 29797908
Drug: Governor vessel
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Governor vessel daoqi method of acupuncture combined with estazolam (2 mg, taken 30 min before sleeping)
Study: 29797908
Drug: Estazolam alone
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam alone (2 mg, taken 30 min before sleeping)
Study: 17605483
Drug: External bleaching
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External bleaching treatment (bleaching gel for 60 minutes, followed by in-office bleaching and 2-week home bleaching for 1 hour daily)
Study: 15843228
Drug: Stress doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress doses of hydrocortisone (100 mg loading dose followed by continuous infusion of 0.18 mg/kg/h for 6 days)
Study: 9457193
Drug: Pulse-spray pharmacomechanical
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-spray pharmacomechanical thrombolysis (PSPMT)
Study: 7823364
Drug: Topical rhPDGF‐BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rhPDGF‐BB (2.2 micrograms/cm2 of ulcer area)
Study: 7823364
Drug: Topical rhPDGF‐BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rhPDGF‐BB
Study: 7823364
Drug: Topical rhPDGF‐BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rhPDGF‐BB and Placebo
Study: 2248812
Drug: i.m. ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. ketorolac trometamol 30 mg
Study: 7309298
Drug: SROC 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: SROC 160 (160 mg oxprenolol slow-release + 20 mg chlorthalidone once daily)
Study: 7309298
Drug: COC 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: COC 80 (80 mg oxprenolol + 10 mg chlorthalidone twice daily)
Study: 30657033
Drug: C. spinosa
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. spinosa oxymel (10 mL/thrice daily for 3 months)
Study: 24158337
Drug: Group IM
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group IM (immediately loaded implants)
Study: 24158337
Drug: Group NL
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group NL (nonloaded implants)
Study: 17989948
Drug: Hydrosome wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrosome wound gel
Study: 7834260
Drug: High-frequency electroconvulsive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency electroconvulsive therapy (ECT)
Study: 28233128
Drug: 1210-nm laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1210-nm laser treatment on one breast
Study: 28233128
Drug: 1210-nm laser
Normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1210-nm laser treatment
Study: 22281786
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily (Group A, 30 patients)
Study: 22281786
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg every other day (Group B, 30 patients)
Study: 23212610
Drug: Oxycodone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (15 mg, oral)
Study: 17354119
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg, oral)
Study: 12084605
Drug: Omapatrilat 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 2.5 mg
Study: 14751650
Drug: Omapatrilat 10
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 10 mg
Study: 12084605
Drug: Control (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2.5 mg)
Study: 9470006
Drug: Milk preparation
Normalized name: human milk preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk preparation (skimmed milk enriched with oleic acid)
Study: 2650517
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg/2 minutes followed by 0.35 mg/kg/2 minutes if needed)
Study: 2650517
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem after placebo